Gilead Viread Rep Retraining Program Requested In FDA Warning Letter
Executive Summary
FDA is requesting that Gilead Sciences retrain its Viread sales reps following allegedly misleading claims of safety and efficacy for the anti-HIV agent cited in a July 29 warning letter to the company